Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06330064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06330064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 10, 2024
Completion date
July 25, 2028
Enrollment
680 (estimated)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic solid tumors